SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15 (d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 19, 2005
United Therapeutics Corporation
(Exact Name of Registrant as Specified in Charter)
|
Delaware |
|
000-26301 |
|
52-1984749 |
|
(State or Other |
|
(Commission |
|
(I.R.S. Employer |
|
|
|
|
|
|
|
1110 Spring Street |
|
|
||
|
Silver Spring, MD |
|
20910 |
||
|
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s telephone number, including area code:
(301) 608-9292
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events.
On December 19, 2005, United Therapeutics Corporation issued a press release announcing positive preliminary results of its 45-patient placebo-controlled TRUST trial of intravenous Remodulin. A copy of this press release is attached hereto as Exhibit 99.1.
Item 9.01. Exhibits
(c) Exhibits
|
Exhibit No. |
Description of Exhibit |
|
|
|
|
99.1 |
Press release dated December 19, 2005 |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
UNITED THERAPEUTICS CORPORATION |
||
|
|
|
|
||
|
Dated: December 20, 2005 |
|
By: |
/s/ Paul A. Mahon |
|
|
|
|
Name: |
Paul A. Mahon |
|
|
|
|
Title: |
General Counsel |
|
3